Detail akcie Repligen Corp online

Business Summary: Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Repligen Corp revenues decreased 11% to $305.4M. Net income decreased 89% to $5.4M. Revenues reflect Europe segment decrease of 18% to $105.4M, APAC/Other segment decrease of 31% to $48.8M. Net income also reflects biopharmaceutical segment income decrease of 82% to $3.5M. Basic Earnings per Share excluding Extraordinary Items decreased from $0.88 to $0.10.